The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | MM has a bright future: highlights from ASH
Mark Bustoros, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses his highlights in the field of multiple myeloma (MM) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Dr Bustoros points to the Phase III MAIA trial (NCT02252172), which evaluated the addition of daratumumab to lenalidomide/dexamethasone (D-Rd) vs. Rd alone in transplant-ineligible newly diagnosed MM. Dr Busteros also discusses other trials hoping to improve the outlook for patients and reshape the therapeutic landscape.
